Infant malaria vaccine is promising
Dr Pedro Alonso of the Manhica Health Research Centre in Mozambique and colleagues, did a double-blind trial of 214 infants in Mozambique to test the safety, immunogenicity, and efficacy of the malaria vaccine RTS,S/AS02D.
Children were randomly assigned to receive three doses of the vaccine or hepatitis B vaccine Energix-B (as a control) at ages 10 weeks, 14 weeks and 18 weeks, as well as routine immunisation vaccines given at eight, 12, and 16 weeks of age.
They found that the vaccine was safe (the primary purpose of the trial), since there were no vaccine-related serious adverse events in either the vaccine or control groups, nor an imbalance in unsolicited adverse events between the two groups.
They also found that for children vaccinated the risk of contracting new malaria infections was reduced by 65%’compared with a previous efficacy of 45% reported in a trial of children aged one to four years.
The authors, who are also attached to the Hospital Clinic of the Universitat de Barcelona in Spain, pointed out that all study participants were provided with free-insecticide-treated bednets and their homes were twice sprayed with insecticide.
‘The trial was undertaken in an area of high transmission, but in the context of renewed and intense malaria control activities…the future use and deployment of a malaria vaccine should be seen in the context of comprehensive malaria control programmes,’ they said.
The authors concluded that the study provided evidence of a strong association between vaccine induced antibodies and reduction of risk of malaria infection. ‘This is of great significance because up until now, immunogenicity was a marker of response with no clearly proven relation to protection, which in turn could only be established with a clinical trial.
‘This finding needs to be corroborated further in other trials, but this observation might be important in the clinical development plan of this vaccine,’ the authors said. ‘ Health-e News Service.
Author
Health-e News is South Africa's dedicated health news service and home to OurHealth citizen journalism. Follow us on Twitter @HealtheNews
Republish this article
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Unless otherwise noted, you can republish our articles for free under a Creative Commons license. Here’s what you need to know:
You have to credit Health-e News. In the byline, we prefer “Author Name, Publication.” At the top of the text of your story, include a line that reads: “This story was originally published by Health-e News.” You must link the word “Health-e News” to the original URL of the story.
You must include all of the links from our story, including our newsletter sign up link.
If you use canonical metadata, please use the Health-e News URL. For more information about canonical metadata, click here.
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week”)
You have no rights to sell, license, syndicate, or otherwise represent yourself as the authorized owner of our material to any third parties. This means that you cannot actively publish or submit our work for syndication to third party platforms or apps like Apple News or Google News. Health-e News understands that publishers cannot fully control when certain third parties automatically summarise or crawl content from publishers’ own sites.
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually.
If you share republished stories on social media, we’d appreciate being tagged in your posts. You can find us on Twitter @HealthENews, Instagram @healthenews, and Facebook Health-e News Service.
You can grab HTML code for our stories easily. Click on the Creative Commons logo on our stories. You’ll find it with the other share buttons.
If you have any other questions, contact info@health-e.org.za.
Infant malaria vaccine is promising
by Health-e News, Health-e News
October 16, 2007